Patents by Inventor Philip Marks
Philip Marks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100310045Abstract: X-ray apparatus comprises a linear accelerator adapted to produce a beam of electrons at one of at least two selectable energies and being controlled to change the selected energy on a periodic basis, and a target to which the beam is directed thereby to produce a beam of x-radiation, the target being non-homogenous and being driven to move periodically in synchrony with the change of the selected energy. In this way, the target can move so that a different part is exposed to the electron beam when different pulses arrive. This enables the appropriate target material to be employed depending on the selected energy. The easiest form of periodic movement for the target is likely to be a rotational movement. The target can be immersed in a coolant fluid such as water. The linear accelerator can be of the type disclosed in WO2006/097697A1. The target preferably contains at least one exposed area of tungsten and/or at least one exposed area of carbon.Type: ApplicationFiled: December 21, 2007Publication date: December 9, 2010Applicants: ELEKTA AB (PUBL), THE INSTITUTE OF CANCER RESEARCHInventors: Kevin John Brown, Maria Giulia Thompspm, Vibeke Nordmark Hansen, Philip Mark Evans, David Anthony Roberts
-
Patent number: 7807240Abstract: A multilayer white polymeric film having a core layer with an optical transmission density greater than 2.0, a white polyester outer layer on either side of the core layer and an ink receptive layer on the outer surface of the white polyester layers.Type: GrantFiled: August 31, 2006Date of Patent: October 5, 2010Assignee: DuPont Teijin Films U.S. Limited PartnershipInventors: John Francis, Philip Mark Rutter
-
Publication number: 20100247509Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.Type: ApplicationFiled: December 1, 2005Publication date: September 30, 2010Inventors: Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, Kei Roger Aoki, Joseph Francis, Lance Steward
-
Patent number: 7799835Abstract: The present invention provides, e.g., methods to recycle and/or reduce plastic, non-plastic, or a combination thereof, from a waste stream. The methods of the present invention include contacting the plastic waste with infrared (IR) energy at one or more frequencies and at one or more intensities, over a period of time effective to heat plastic present in the plastic waste.Type: GrantFiled: March 4, 2004Date of Patent: September 21, 2010Assignee: Next-Tec, Ltd.Inventors: Peter Anthony Smith, Adam J. Koffler, Philip Mark Smith
-
Publication number: 20100209248Abstract: A system for the structural monitoring of blades 1 on a wind turbine. Each blade 1 has respective optical fibre bragg grating sensors 5. The system has a number of input connectors, which connect to the strain sensors 5 of respective blades 1. A single output connector connects to a data processing device 3 which processes signals from the strain sensors 5. The input connectors each have a signal path to the output connector that is different in length to the signal path from the other input connectors, such that signals from a given blade 1 can be identified at the data processing device 3 by the time of arrival of the signals. The system has the advantage that the each of the blades 1, including the sensors attached to it or embedded within it can be identical and therefore interchangeable.Type: ApplicationFiled: August 20, 2007Publication date: August 19, 2010Inventors: Mark Volanthen, Philip Mark Rhead, Martin Peter William Jones, Glynn David Lloyd
-
Patent number: 7691923Abstract: Curable wood particle composites curable by the Michael addition reaction in the presence of strong base catalyst are disclosed, along with a method for making those curable wood particle composites. Cured wood particle composites are also disclosed, along with a method of making those cured wood particle composites.Type: GrantFiled: May 1, 2008Date of Patent: April 6, 2010Assignee: Rohm and Haas CompanyInventors: Eric Gustave Lundquist, Allen Philip Marks
-
Patent number: 7687555Abstract: Curable wood particle composites curable by the Michael addition reaction in the presence of weak base catalyst are disclosed, along with a method for making those curable wood particle composites. Cured wood particle composites are also disclosed, along with a method of making those cured wood particle composites.Type: GrantFiled: May 1, 2008Date of Patent: March 30, 2010Assignee: Rohm and Haas CompanyInventors: Eric Gustave Lundquist, Allen Philip Marks
-
Patent number: 7674470Abstract: Antigenic compositions are provided comprising a single chain polypeptide comprising first and second domains, wherein said first domain is a clostridial neurotoxin light chain or a fragment or a variant thereof and is capable of cleaving one or more vesicle or plasma membrane associated proteins essential to exocytosis; and said second domain is a clostridial neurotoxin heavy chain HN portion or a fragment or a variant thereof, wherein said second domain is capable of (i) translocating the polypeptide into a cell or (ii) increasing the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both translocating the polypeptide into a cell and increasing the solubility of the polypeptide compared to the solubility of the first domain on its own; and wherein the second domain lacks a functional C-terminal part of a clostridial neurotoxin heavy chain designated HC thereby rendering the polypeptide incapable of binding to cell surface receptors that are the natural cell surType: GrantFiled: March 11, 2005Date of Patent: March 9, 2010Assignees: Health Protection Agency, Syntaxin LimitedInventors: Charles Clifford Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Publication number: 20100034802Abstract: Use of a therapeutic molecule, for the treatment of specific pain conditions, wherein the therapeutic molecule is a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent.Type: ApplicationFiled: June 1, 2007Publication date: February 11, 2010Applicants: SYNTAXIN LIMITED, ALLERGAN, INC.Inventors: Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, K. Roger Aoki, Joseph Francis, Lance Steward
-
Patent number: 7659092Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.Type: GrantFiled: August 6, 2007Date of Patent: February 9, 2010Assignees: Syntaxin, Ltd., Allergan, Inc.Inventors: Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, Kei Roger Aoki, Joseph Francis, Lance Steward
-
Publication number: 20100022751Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: ApplicationFiled: February 11, 2009Publication date: January 28, 2010Applicants: SYNTAXIN LIMITED, THE HEALTH PROTECTION AGENCYInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Patent number: 7640130Abstract: Systems and methods for effectuating verification and certification of verifiable devices. Preferably, but not necessarily, such certification occurs or is communicated remotely. A verifiable device may be directly or indirectly connected to an appropriate regulatory agency through a communication mechanism. One or more tests may be performed on the verifiable device to verify that the device is functioning properly. The test results are directly or indirectly transmitted to the regulatory agency. If the tests were passed then the verifiable device may be approved for use. When self-certification or remote certification is provided for, the need for in-person verification and certification procedures by agency personnel may be eliminated.Type: GrantFiled: October 24, 2007Date of Patent: December 29, 2009Assignee: Mettler-Toledo, Inc.Inventors: John Scott Churan, Philip Mark Metzler
-
Publication number: 20090274708Abstract: Antigenic compositions are provided comprising a single chain polypeptide comprising first and second domains, wherein said first domain is a clostridial neurotoxin light chain or a fragment or a variant thereof and is capable of cleaving one or more vesicle or plasma membrane associated proteins essential to exocytosis; and said second domain is a clostridial neurotoxin heavy chain HN portion or a fragment or a variant thereof, wherein said second domain is capable of (i) translocating the polypeptide into a cell or (ii) increasing the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both translocating the polypeptide into a cell and increasing the solubility of the polypeptide compared to the solubility of the first domain on its own; and wherein the second domain lacks a functional C-terminal part of a clostridial neurotoxin heavy chain designated HC thereby rendering the polypeptide incapable of binding to cell surface receptors that are the natural cell surType: ApplicationFiled: March 6, 2009Publication date: November 5, 2009Applicants: Health Protection Agency, Syntaxin LimitedInventors: Charles Clifford SHONE, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Publication number: 20090246827Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: ApplicationFiled: July 17, 2008Publication date: October 1, 2009Applicants: SYNTAXIN LIMITED, THE HEALTH PROTECTION AGENCYInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Publication number: 20090148888Abstract: A single polypeptide is provided which comprises first and second domains. The first domain enables the polypeptide to cleave one or more vesicle or plasma-membrane associated proteins essential to exocytosis, and the second domain enables the polypeptide to be translocated into a target cell or increases the solubility of the polypeptide, or both. The polypeptide thus combines useful properties of a clostridial toxin, such as a botulinum or tetanus toxin, without the toxicity associated with the natural molecule. The polypeptide can also contain a third domain that targets it to a specific cell, rendering the polypeptide useful in inhibition of exocytosis in target cells. Fusion proteins comprising the polypeptide, nucleic acids encoding the polypeptide and methods of making the polypeptide are also provided. Controlled activation of the polypeptide is possible and the polypeptide can be incorporated into vaccines and toxin assays.Type: ApplicationFiled: January 27, 2009Publication date: June 11, 2009Applicants: SYNTAXIN LIMITED, THE HEALTH PROTECTION AGENCYInventors: Clifford Charles Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Publication number: 20090035822Abstract: A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.Type: ApplicationFiled: August 6, 2007Publication date: February 5, 2009Inventors: Keith Foster, John Chaddock, Philip Marks, Patrick Stancombe, Kei Roger Aoki, Joseph Francis, Lance Steward
-
Publication number: 20090004174Abstract: The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endocome within the target cell; a protease cleaving site at which site the fusion protein is cleavable by the protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and the translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell.Type: ApplicationFiled: December 1, 2005Publication date: January 1, 2009Applicant: SYNTAXIN LIMITEDInventors: Keith Alan Foster, John Chaddock, Philip Marks, Patrick Stancombe, Lyndsey Durose
-
Publication number: 20080287571Abstract: Curable wood particle composites curable by the Michael addition reaction in the presence of weak base catalyst are disclosed, along with a method for making those curable wood particle composites. Cured wood particle composites are also disclosed, along with a method of making those cured wood particle composites.Type: ApplicationFiled: May 1, 2008Publication date: November 20, 2008Inventors: Eric Gustave Lundquist, Allen Philip Marks
-
Publication number: 20080287572Abstract: Curable wood particle composites curable by the Michael addition reaction in the presence of strong base catalyst are disclosed, along with a method for making those curable wood particle composites. Cured wood particle composites are also disclosed, along with a method of making those cured wood particle composites.Type: ApplicationFiled: May 1, 2008Publication date: November 20, 2008Inventors: Eric Gustave Lundquist, Allen Philip Marks
-
Patent number: D625977Type: GrantFiled: February 25, 2010Date of Patent: October 26, 2010Assignee: Vertex Stone and Chinaware Ltd.Inventors: Brian John Watson, Anthony Arthur Wills, Philip Mark Hall